Abstract The recent introduction of High-Efficacy Therapies (HETs) in clinical practice has drastically reduced the frequency of acute inflammatory episodes…
Abstract Cannabidiol (CBD) is one of the most studied compounds of Cannabis sativa and has attracted significant interest due to…
Keywords: Multiple sclerosis, Single nucleotide polymorphisms, Nabiximols, Spasticity, ABCB1 Authors: Alessandra Gemma, Marco Mauri, Paola Banfi, Maurizio Versino, Alen Zollo,…
Abstract Background: Cannabinoid oro-mucosal spray nabiximols is approved for patients with moderate to severe multiple sclerosis spasticity (MSS) resistant to…
Abstract Aim: Cannabis-based medication has recently been made available in the NHS for reducing pain and spasticity in patients with…
Abstract In light of the current International Association for the Study of Pain (IASP) clinical practice guidelines (CPGs) and the…
Abstract Background: Glioblastoma (GBM) is the most common adult malignant brain tumour, with an incidence of 5 per 100,000 per…
Abstract Background: Spasticity affects 54% of multiple sclerosis (MS) patients at disease onset, but this rate gradually increases with disease…
Abstract Background: Over 80% of individuals with multiple sclerosis (MS) experience MS-associated spasticity (MSS). In many European countries, after failure…
Abstract Background and purpose: Randomized controlled trials and observational studies of nabiximols oromucosal spray in patients with multiple sclerosis (MS)…